Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H2 2019.

Global Markets Direct’s, ‘Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H2 2019’, provides in depth analysis on Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Immunology under development targeting Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

  • Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)

- The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects

- The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Biomics Biotechnologies Co Ltd

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

IMV Inc

MimiVax LLC

Optimum Therapeutics LLC

Oxford Vacmedix UK Ltd

Polyplus-Transfection SA

Stemline ...

Biomics Biotechnologies Co Ltd

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

IMV Inc

MimiVax LLC

Optimum Therapeutics LLC

Oxford Vacmedix UK Ltd

Polyplus-Transfection SA

Stemline Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development

Biomics Biotechnologies Co Ltd

Boehringer Ingelheim International GmbH

Canget BioTekpharma LLC

IMV Inc

MimiVax LLC

Optimum Therapeutics LLC

Oxford Vacmedix UK Ltd

Polyplus-Transfection SA

Stemline Therapeutics Inc

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles

Antibody to Target Survivin for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BGA-005 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1644 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BKM-1740 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DPX-Survivac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FL-118 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MV-2C2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MX-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OVM-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SL-701 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UC-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Autoimmune Diseases and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Colon Carcinoma and Lymphoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Neuroblastoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target BIRC5 for Relapsed Multiple Myeloma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones

Featured News & Press Releases

Jun 12, 2019: New Phase 2 clinical trial results continue to demonstrate potential clinical benefit of IMV’s DPX-survivac in combination with Merck’s Keytruda in patients with DLBCL

Jun 04, 2019: IMV to provide update on phase 2 clinical results with Merck Keytruda in DLBCL by means of conference Call and Webcast

Jun 01, 2019: Phase II trial shows favorable response for patients receiving combination therapy with SurVaxM

Jun 01, 2019: Imv presents new positive data from phase 2 monotherapy arm of its decide1 trial in advanced ovarian cancer and continued duration of clinical benefits to patients with progression free survival

May 16, 2019: IMV to present new data at 2019 ASCO annual meeting from its Phase 2 clinical trial evaluating DPX-Survivac in Ovarian Cancer

Apr 18, 2019: IMV to provide updated clinical data at 2019 ASCO annual meeting on lead candidate DPX-Survivac in Ovarian Cancer and other solid tumors

Mar 26, 2019: Initial phase 2 data from an IMV clinical study continues to demonstrate DPX-Survivac's prior trend as a potential monotherapy treatment for advanced ovarian cancer

Jan 29, 2019: IMV announces clinical update for DPX-Survivac program in ovarian cancer following positive feedback from U.S. FDA

Dec 13, 2018: IMV presents updated positive data from phase 1b/2 combination clinical trial in advanced ovarian cancer at 2018 ESMO Immuno-Oncology Congress

Dec 10, 2018: IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac's Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018

Nov 28, 2018: Brain Cancer Immunotherapy SurVaxM extends survival, even in hard-to-treat patients

Nov 22, 2018: IMV amends Phase Ib/II trial of recurrent ovarian cancer drug

Nov 16, 2018: Stemline Therapeutics announces oral presentation of SL-701 phase 2 data in second-line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)

Oct 16, 2018: Stemline Therapeutics announces SL-701 clinical data to be featured, including an Oral Presentation, at upcoming ESMO 2018 Congress

Sep 18, 2018: IMV announces early positive results from phase 2 clinical trial of lead candidate DPX-Survivac in combination with Merck’s Keytruda in patients with DLBCL

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indications, H2 2019

Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products under Investigation by Universities/Institutes, H2 2019

Products under Investigation by Universities/Institutes, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Biomics Biotechnologies Co Ltd, H2 2019

Pipeline by Boehringer Ingelheim International GmbH, H2 2019

Pipeline by Canget BioTekpharma LLC, H2 2019

Pipeline by IMV Inc, H2 2019

Pipeline by MimiVax LLC, H2 2019

Pipeline by Optimum Therapeutics LLC, H2 2019

Pipeline by Oxford Vacmedix UK Ltd, H2 2019

Pipeline by Polyplus-Transfection SA, H2 2019

Pipeline by Stemline Therapeutics Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Dormant Products, H2 2019 (Contd..2), H2 2019

Discontinued Products, H2 2019

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number ...

List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports